<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04239950</url>
  </required_header>
  <id_info>
    <org_study_id>MND2112H33</org_study_id>
    <secondary_id>20191474</secondary_id>
    <nct_id>NCT04239950</nct_id>
  </id_info>
  <brief_title>Efficacy of Ethyl Icosapentate in Patients With Severe Hypertriglyceridemia</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Parallel-group, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ethyl Icosapentate in Patients With Severe Hypertriglyceridemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mochida Pharmaceutical Company, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sumitomo Pharmaceutical (Suzhou) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mochida Pharmaceutical Company, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of ethyl icosapentate in&#xD;
      Chinese patients with severe hypertriglyceridemia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of change from baseline in serum triglyceride level at 12 weeks after the start of study drug administration</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events after the start of study drug administration</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of change from baseline in serum total cholesterol level at 12 weeks after the start of study drug administration</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of change from baseline in serum low-density lipoprotein cholesterol (LDL-C) level at 12 weeks after the start of study drug administration</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of change from baseline in serum high-density lipoprotein cholesterol (HDL-C) level at 12 weeks after the start of study drug administration</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse drug reaction after the start of study drug administration</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, orally, twice daily after breakfast and dinner for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ethyl Icosapentate 1.8g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ethyl Icosapentate 0.9g, orally, twice daily after breakfast and dinner for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ethyl Icosapentate 3.6g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ethyl Icosapentate 1.8g, orally, twice daily after breakfast and dinner for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethyl Icosapentate</intervention_name>
    <description>Ethyl Icosapentate</description>
    <arm_group_label>Ethyl Icosapentate 1.8g</arm_group_label>
    <arm_group_label>Ethyl Icosapentate 3.6g</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Patients whose serum Triglyceride (TG) level (fasting) from week -6 to week -4 is 500&#xD;
             mg/dL or higher and less than 2,000 mg/dL&#xD;
&#xD;
          2. Patients who receive instructions for lifestyle improvement and are able to comply&#xD;
             with all instructions throughout the study participation period&#xD;
&#xD;
          3. Patients who are 18 to &lt; 75 years of age, regardless of sex, at the time of informed&#xD;
             consent&#xD;
&#xD;
          4. Patients who have provided written consent to participate in this clinical trial&#xD;
&#xD;
          5. Patients whose serum TG level (fasting) is 500 mg/dL or higher and less than 2,000&#xD;
             mg/dL at Visit 2 (Week -2)&#xD;
&#xD;
          6. Patients whose serum TG level (fasting) is 500 mg/dL or higher and less than 2,000&#xD;
             mg/dL at Visit 3 (Week -1)&#xD;
&#xD;
          7. Patients in whom the difference between Visit 2 (Week -2) and Visit 3 (Week -1) in&#xD;
             serum TG level (fasting) is not more than 50% of the higher value&#xD;
&#xD;
          8. Outpatients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients whose HbA1c from week -6 to week -4 is 8.0% or higher&#xD;
&#xD;
          2. Patients whose Alanine Aminotransferase (ALT) or Aspartate aminotransferase (AST) from&#xD;
             week -6 to week -4 is more than 3 times the upper limit of normal&#xD;
&#xD;
          3. Patients with, or with a history of, angina pectoris or myocardial infarction&#xD;
&#xD;
          4. Patients with a history of percutaneous transluminal coronary angioplasty or coronary&#xD;
             artery bypass grafting&#xD;
&#xD;
          5. Patients with familial lipoprotein lipase (LPL) deficiency, familial apolipoprotein&#xD;
             C-II (apo C-II) deficiency, or familial type III, IV hyperlipidemia&#xD;
&#xD;
          6. Patients with hypothyroidism, Cushing's syndrome, acromegaly, nephrotic syndrome,&#xD;
             chronic renal failure, systemic lupus erythematosus, myeloma, or nonalcoholic&#xD;
             steatohepatitis (NASH)&#xD;
&#xD;
          7. Patients with hyperlipidemia induced by drugs (e.g., corticosteroids, beta-blockers,&#xD;
             contraceptives, interferons, retinoids, and diuretics)&#xD;
&#xD;
          8. Patients with, or with a history of, alcohol dependence or abuse or patients whose&#xD;
             hyperlipidemia is presumed to be primarily caused by alcohol&#xD;
&#xD;
          9. Patients with aortic aneurysm or who have undergone aortic aneurysmectomy within the&#xD;
             last 6 months&#xD;
&#xD;
         10. Patients with uncontrollable hypertension (patients with a systolic blood pressure of&#xD;
             ≥180 mmHg or a diastolic blood pressure of ≥110 mmHg in a sitting position at Visit 1&#xD;
             (Week -4))&#xD;
&#xD;
         11. Patients with, or with a history of, pancreatitis or patients suspected as&#xD;
             pancreatitis by examination, etc&#xD;
&#xD;
         12. Patients with a diagnosis of complication of pancreas or bile duct-related neoplastic&#xD;
             disease&#xD;
&#xD;
         13. Patients with type 1 diabetes mellitus or type 2 diabetes mellitus requiring insulin&#xD;
             therapy&#xD;
&#xD;
         14. Patients with any of the following hemorrhagic findings within the last 6 months:&#xD;
&#xD;
               -  Patients with, or with a history of, clinically significant hemorrhagic disease&#xD;
                  (e.g., cerebral hemorrhage, hemophilia, capillary fragility, gastrointestinal&#xD;
                  [GI] ulcer, urinary tract hemorrhage, hemoptysis, vitreous hemorrhage)&#xD;
&#xD;
               -  Patients with clinically significant bleeding tendency (e.g., menorrhagia,&#xD;
                  frequent epistaxis)&#xD;
&#xD;
               -  Patients with, or with a history of, severe trauma&#xD;
&#xD;
               -  Patients with a history of surgery requiring blood transfusion&#xD;
&#xD;
         15. Patients who have taken any EPA product&#xD;
&#xD;
         16. Patients who have received a PCSK9 (human proprotein convertase subtilisin/kexin type&#xD;
             9) inhibitor to treat hyperlipidemia&#xD;
&#xD;
         17. Patients who have taken antihyperlipidemic drugs within the last 4 weeks&#xD;
&#xD;
         18. Pregnant, possibly pregnant, or lactating women&#xD;
&#xD;
         19. Patients with a history of hypersensitivity to polyunsaturated fatty acids or gelatin&#xD;
&#xD;
         20. Patients with, or with a history of, malignant tumor&#xD;
&#xD;
         21. Patients with any serious disease, including hepatic, renal, hematologic, respiratory,&#xD;
             GI, cardiovascular, psychological, neurologic, metabolic, and electrolyte disorders,&#xD;
             or hypersensitivity&#xD;
&#xD;
         22. Patients who have received any other investigational drug within the last 3 months&#xD;
&#xD;
         23. Patients who are judged by the principal (or sub-) investigator to be ineligible as a&#xD;
             study subject for any other reason&#xD;
&#xD;
         24. Patients with a systolic blood pressure of ≥180 mmHg or a diastolic blood pressure of&#xD;
             ≥110 mmHg at Visit 2 (Week -2))&#xD;
&#xD;
         25. Patients who have changed the dosage of antidiabetic drug (except insulin) or who have&#xD;
             switched from one drug to another since Visit 1 (Week -4)&#xD;
&#xD;
         26. Patients with a systolic blood pressure of ≥180 mmHg or a diastolic blood pressure of&#xD;
             ≥110 mmHg at Visit 3 (Week -1)&#xD;
&#xD;
         27. Patients with an HbA1c level of ≥8.0% at Visit 2 (Week -2)&#xD;
&#xD;
         28. Patients whose ALT or AST is more than 3 times the upper limit of normal at Visit 2&#xD;
             (Week -2)&#xD;
&#xD;
         29. Patients with a systolic blood pressure of ≥180 mmHg or a diastolic blood pressure of&#xD;
             ≥110 mmHg at Visit 4 (Week 0)&#xD;
&#xD;
         30. Patients with an HbA1c level of ≥8.0% at Visit 3 (Week -1)&#xD;
&#xD;
         31. Patients whose ALT or AST is more than 3 times the upper limit of normal at Visit 3&#xD;
             (Week -1)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takuya Mori</last_name>
    <role>Study Director</role>
    <affiliation>Mochida Pharmaceutical Company, Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mochida Clinical Research Department</last_name>
    <phone>+81-3-3225-6331</phone>
    <email>clinical.trials.contact@mochida.co.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mochida Public Relations Office</last_name>
    <email>webmaster@mochida.co.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mochida Investigational sites</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 20, 2020</study_first_submitted>
  <study_first_submitted_qc>January 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eicosapentaenoic acid ethyl ester</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

